For instance, immunomodulators that have the capacity to induce IL-12 and IFN-γ with novel SMAD3/4 or STAT3 and STAT6 inhibitory molecules are potential targeted mixtures of polarizing the beneficial immune cells within tumor microenvironment. This evidence concerns the gene IFNG and neoplasm.